132 related articles for article (PubMed ID: 23283649)
1. Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
Livi L; Bonomo P; Meattini I; Simontacchi G; Greto D; Desideri I; Meacci F; Scotti V; Cecchini S; Nori J; Sanchez LJ; Orzalesi L; Paiar F; Biti G
Med Oncol; 2013 Mar; 30(1):434. PubMed ID: 23283649
[TBL] [Abstract][Full Text] [Related]
2. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
6. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
Cannita K; Paradisi S; Cocciolone V; Bafile A; Rinaldi L; Irelli A; Lanfiuti Baldi P; Zugaro L; Manetta R; Alesse E; Ricevuto E; Ficorella C
Cancer Med; 2016 Sep; 5(9):2232-9. PubMed ID: 27416882
[TBL] [Abstract][Full Text] [Related]
7. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
9. First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
Masuda N; Takahashi M; Nakagami K; Okumura Y; Nakayama T; Sato N; Kanatani K; Tajima K; Kashiwaba M
Jpn J Clin Oncol; 2017 May; 47(5):385-392. PubMed ID: 28158579
[TBL] [Abstract][Full Text] [Related]
10. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
Fabi A; Russillo M; Ferretti G; Metro G; Nisticò C; Papaldo P; De Vita F; D'Auria G; Vidiri A; Giannarelli D; Cognetti F
BMC Cancer; 2012 Oct; 12():482. PubMed ID: 23083011
[TBL] [Abstract][Full Text] [Related]
11. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Robert NJ; Saleh MN; Paul D; Generali D; Gressot L; Copur MS; Brufsky AM; Minton SE; Giguere JK; Smith JW; Richards PD; Gernhardt D; Huang X; Liau KF; Kern KA; Davis J
Clin Breast Cancer; 2011 Apr; 11(2):82-92. PubMed ID: 21569994
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Martín M; Makhson A; Gligorov J; Lichinitser M; Lluch A; Semiglazov V; Scotto N; Mitchell L; Tjulandin S
Oncologist; 2012; 17(4):469-75. PubMed ID: 22467666
[TBL] [Abstract][Full Text] [Related]
14. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Salvador J; Manso L; de la Haba J; Jaen A; Ciruelos E; de Villena MC; Gil M; Murias A; Galan A; Jara C; Bayo J; Baena JM; Casal J; Mel JR; Blancas I; Sanchez Rvira P
Clin Transl Oncol; 2015 Feb; 17(2):160-6. PubMed ID: 25119930
[TBL] [Abstract][Full Text] [Related]
15. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
[TBL] [Abstract][Full Text] [Related]
18. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
